Bravo, Endoflip, and patient meeting with physician

SIMPLIFY THE DIAGNOSTIC JOURNEY

Two simple tests can transform how you evaluate esophageal motility disorders and GERD:

  • Endoflip™ impedance planimetry system
  • Bravo™ calibration-free reflux testing system

DOWNLOAD BROCHURE

Graphic illustrating the stat that one in three people on antacids doesn't actually have GERD.

DIFFICULT TO DIAGNOSE

CHALLENGING TO MANAGE

Esophageal disease patients can have similar symptoms — but their diseases may be different. This means tests aren't always conclusive and treatment isn't always effective:

  • Up to 50 percent of endoscopies for predominant esophageal symptoms are negative.1-3
  • Nearly one-third of patients with suspected PPI-resistant nonerosive reflux disease may have an undiagnosed primary esophageal motility disorder.4
  • One in three patients referred with ongoing symptoms while using PPIs doesn’t have GERD.5

MOVE BEYOND SYMPTOMS WITH 2 SIMPLE TESTS

Our solutions help you objectively evaluate the root cause of esophageal motility disorders and GERD:

  • Endoflip™ impedance planimetry system measures pressure and dimensions in real-time to evaluate suspected esophageal motility disorders. Impedance planimetry of the upper gastrointestinal tract adds meaningfully to diagnostic evaluation and therapeutic decision-making.6
  • Bravo™ calibration-free reflux testing system measures acid levels in the esophagus for up to 96 hours. Early diagnostic testing before long-term PPI initiation may help define which patients can avoid PPI use and potentially prevent excess PPI dependence.7

VIEW BROCHURE TO LEARN MORE
Graphic illustrating where in the esophagus and chest patients experience symptoms of esophageal disease.

YOUR PARTNER IN ESOPHAGEAL CARE

Learn how our comprehensive portfolio can help you care for patients across the care continuum — from GERD to Barrett's esophagus.

Explore Content

SPEAK WITH A REPRESENTATIVE

For additional information about the EndoflipTM or BravoTM systems, complete a brief form to speak directly with a Medtronic sales representative.

REQUEST INFORMATION
Representative Consulting with a Doctor

CAUTIONS AND RISKS

Caution: Federal law restricts these devices to sale by or on the order of a licensed healthcare practitioner. Rx only.

Risk Information: Similar to most procedures, the products featured here have inherent procedure risks associated. Please refer to the individual product user manuals for detailed information.

1

Laine, Goldmann et al. In the clinic: gastroesophageal reflux disease. Annals of Internal Medicine. 2008 Aug 5; ITC2: 1-16.

2

Kahrilas PJ. Gastroesophageal reflux disease. N Engl J Med. 2008; 359: 1700-7.

3

Ronkainen et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129: 1825-1831.

4

Kawamura O, Hosaka H, Shimoyama Y et al. Evaluation of proton pump inhibitor resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring. Digestion. 2015;91(1):19-25.

5

Herregods, T. V. K., et al. Patients with refractory reflux symptoms often do not have GERD: Neurogastroenterology & Motility. 2015; 27(9): 1267-1273.

6

Ahuja NK, Agnihotri A, Lynch KL, et al. Esophageal distensibility measurement: impact on clinical management and procedure length. Diseases Of The Esophagus: Official Journal Of The International Society For Diseases Of The Esophagus. 2017;30(8):1-8.

7

Triadafilopoulos G, Zikos T, Regalia K, et al. Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms. Digestive Diseases And Sciences. 2018;63(10):2673-2680. doi:10.1007/s10620-018-5183-4.